WASHINGTON (AP) — The U.S. is purchasing enough doses of a new twice-a-year HIV prevention shot to share with up to 2 million people in poor countries by 2028, the State Department announced Thursday.

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug that offers 100% protection with its twice-yearly injections. It's a landmark ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

DUBLIN--(BUSINESS WIRE)--The "HIV Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for HIV Drugs was valued at US$32.8 Billion in ...

Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...

A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of HIV.

Among patients with HIV with low-to-moderate cardiovascular risk, both former and current exposure to abacavir was associated with an increased risk for major adverse cardiovascular events (MACE) ...

Caremark unit delays adding the company's new HIV prevention drug Yeztugo over pricing concerns. Read more here.

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...